Comparing the current results to its competitors, Alvotech reported Revenue increase in the 4 quarter 2025 by 19.7 % year on year. The sales growth was above Alvotech's competitors' average revenue growth of 5.62 %, achieved in the same quarter.
Alvotech's Comment on Competition and Industry Peers
The company's biosimilars face competition from both originator companies and other biosimilar manufacturers for each product. For AVT02, a biosimilar to Humira, competitors include AbbVie (originator), Amgen, Biocon, Celltrion, Fresenius Kabi, Pfizer, Samsung Bioepis, Sandoz, Boehringer Ingelheim, and King-Friend. AVT04, a biosimilar to Stelara, competes with Johnson & Johnson (originator), Intas, Amgen, Biocon, Celltrion, Formycon, Fresenius Kabi, Gedeon Richter, Samsung Bioepis, Accord, and Bio-Thera. AVT06, a biosimilar to Eylea, faces competition from Regeneron (originator), Amgen, Biocon, Celltrion, Formycon, Samsung Bioepis, Sandoz, STADA, Sam Chun Dang, and Polpharma. AVT03, a biosimilar candidate to Prolia/Xgeva, competes with Amgen (originator), Intas, Biocon, Celltrion, Fresenius Kabi, Gedeon Richter, Mabxience, Samsung Bioepis, Sandoz, Sciencepharma, STADA, Zentiva, Accord, Amneal, Hikma, and Henlius. AVT05, a biosimilar candidate to Simponi, competes with Janssen (originator) and Bio-Thera. AVT23, a biosimilar candidate to Xolair, faces competition from Genentech (originator), Celltrion, and Teva. Originator companies are actively working to expand labels and market positions for their reference products.
Overall company sales advanced by 19.7 % Alvotech outperformed its competitors in this segment and improved market share, to approx. 0.58 %. << More on ALVO Market Share.
*Market share is calculated based on total revenue.
June 4, 2025
Alvotech, a dedicated biotechnology company specializing in the development of high-quality biosimilars, has announced its intention to engage in a private placement of approximately 7.5 million Swedish Depository Receipts (SDRs) and ordinary shares. This financial maneuver comes at a pivotal moment for the company, as it marks a strategic step in bolstering its resources and encouraging growth. The announcement, however, also comes with crucial disclaimers, prohibiting distribution in the United States and several other countries where such actions may conflict with legal requirements. Private Placement DetailsThe upcoming private placement is expected to enhance Alvotech s financial positioning, providing...
November 13, 2024
Alvotech s Strategic Advancements and Financial Performance in 2024: Pioneering the Future of Biosimilars In the rapidly advancing field of biotechnology, biosimilar medicines offer transformative potential to enhance patient access and reduce healthcare costs. Alvotech, a global leader in the development and manufacture of biosimilars, has distinguished itself through significant achievements in 2024. This article provides an in-depth analysis of Alvotech s financial results for the first nine months of 2024, highlights its strategic engagements, and examines its regulatory progress with the European Medicines Agency (EMA) concerning its biosimilar product, AVT06. Financial Overview for the First Nine Mont...
October 10, 2024
European Medicines Agency Accepts Alvotech s Marketing Application for AVT03, a Proposed Biosimilar to Prolia and Xgeva Alvotech, a global biotech entity listed on NASDAQ under the ticker ALVO, has announced a significant milestone in its pursuit of expanding the availability of biosimilar medicines. The European Medicines Agency (EMA) has formally accepted the Marketing Authorisation Application for AVT03, a biosimilar candidate to Prolia and Xgeva, both brand names of the drug denosumab. This acknowledgment from the EMA represents a pivotal step towards potential approval within the European market, marking a substantial progression in Alvotech s mission to offer affordable biotherapeutic alternatives glob...
September 25, 2024
Alvotech (NASDAQ: ALVO), a prominent global biotechnology firm specializing in the development and manufacturing of biosimilar medicines, has announced the initiation of a confirmatory patient study for their biosimilar candidate, AVT16. This candidate is designed to mirror the effects of Entyvio (vedolizumab), a widely used treatment for patients suffering from moderate to severe active Ulcerative Colitis (UC). Study and Design The primary aim of this rigorous study is to assess and compare the efficacy, safety, and immunogenicity of AVT16 against Entyvio. The trial will enroll both male and female participants aged between 18 and 80 who are diagnosed with moderate to severe active Ulcerative Colitis. Thes...
August 15, 2024
In a significant development in the biotechnology sector, the European Medicines Agency (EMA) has confirmed its acceptance of Alvotech s marketing application for AVT06, a proposed biosimilar to Eylea (aflibercept). This news marks a pivotal moment for Alvotech, signaling the company s progress in enhancing access to critical biologics for patients suffering from various eye diseases, such as age-related macular degeneration and diabetic macular edema.Eylea, a blockbuster treatment developed by Regeneron, has garnered widespread acclaim for its efficacy in managing retinal diseases. With the global demand for such biologic therapies growing, Alvotech s advancement into the biosimilar market with AVT06 offers...
June 26, 2024
Alvotech, a leading global biotech company focused on developing and manufacturing biosimilar medicines, has recently made significant developments that will impact its future growth and financial strength. This article examines the key facts surrounding Alvotech s conversion of convertible bonds, the expansion of its alliance with STADA, and its upcoming participation in the prestigious Jefferies Healthcare Conference. These developments highlight Alvotech s continued commitment to innovation and strategic partnerships, positioning the company for further success in the pharmaceutical industry.Fact 1: Majority of Convertible Bonds Converted into Ordinary SharesAlvotech s announcement reveals that holders of...
June 11, 2024
Strengthening Strategic Alliances: Alvotech and STADA Expand Partnership with Denosumab Biosimilar InitiativeIn a decisive move to enhance their commitment to providing high-quality, cost-effective biosimilars, Alvotech and STADA have announced the extension of their strategic alliance to include the biosimilar candidate AVT03. This clinical-stage candidate references Prolia® and Xgeva® (denosumab), vital medicines used in the treatment of osteoporosis and cancer-related bone loss.The extension of the collaboration underscores the mutual ambition of both companies to address critical healthcare needs by developing and marketing biosimilars that offer comparable efficacy and safety to their branded counter...
May 15, 2024
In recent news, Alvotech S.A., a global biotech company, has revealed several significant developments that will have a considerable impact on the company s growth and contribution to global healthcare. With the announcement of their upcoming Annual General Meeting, the strategic partnership agreement with Quallent Pharmaceuticals for the manufacture of a high-concentration interchangeable biosimilar to Humira (adalimumab), and the positive topline results from a confirmatory clinical study for AVT05, a proposed biosimilar to Simponi (golimumab), Alvotech has positioned itself as a frontrunner in the biosimilar medicine industry. Let s delve into the facts and assess their potential impact on the company.Alv...
April 19, 2024
Alvotech, a global biotech company focused on the development and manufacturing of biosimilar medicines, has recently signed a long-term agreement with a strategic partner to improve access to Adalimumab-ryvk in the U.S. market. Adalimumab-ryvk is a high-concentration interchangeable biosimilar to Humira, which received approval from the U.S. Food and Drug Administration (FDA). This agreement aims to address the growing demand for biotherapeutics and provide cost-effective treatment options for patients.Expansion of Access for Adalimumab-ryvk:In a recent announcement, Alvotech revealed a strategic partnership that will further enhance access to Adalimumab-ryvk in the U.S. market. Adalimumab-ryvk is a high-co...
April 16, 2024
In a significant step for psoriasis treatment, Alvotech and the U.S division of Teva Pharmaceutical Industries Ltd recently received a nod of approval from the U.S. Food and Drug Administration (FDA) for their innovative drug, SELARSDI (ustekinumab-aekn). The FDA approval acknowledges the drug as a biosimilar to Stelara (ustekinumab), widely recognized for its effectiveness in managing moderate to severe plaque psoriasis and active psoriatic arthritis in adults and children aged 6 years and above.This development is the outcome of the strategic partnership inked between Teva, a globally reputed pharmaceutical company, and Alvotech, an international biopharmaceutical company focused on the development and man...
Qrons Inc is a biotechnology company that focuses on developing advanced solutions for brain-related injuries and diseases. Their business model revolves around leveraging cutting-edge technology and knowledge in stem cells, neurology, and bioengineering to create innovative therapies and treatments. Qrons Inc aims to provide effective and transformative healthcare solutions by collaborating with medical institutions, research organizations, and industry leaders.
Prokidney Corp is a medical device company that specializes in developing innovative solutions for kidney dialysis treatment. Their business model focuses on designing, manufacturing, and marketing advanced dialysis machines and related consumables to healthcare providers worldwide. Through strategic partnerships and collaborations, Prokidney Corp aims to improve patient outcomes and enhance the overall efficiency of kidney dialysis procedures.
Sources:
Alvotech’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Alvotech versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
